

**ASX RELEASE (ASX: MDR)****MedAdvisor September Quarterly (1Q FY23) Briefing**

**Melbourne, Australia, 25 October 2022** – MedAdvisor Limited (**MedAdvisor** or the **Company**) is pleased to invite shareholders to participate in its September Quarterly briefing.

MedAdvisor is releasing its 1Q FY23 Quarterly Activities Report and Appendix 4C on Friday 28 October 2022, and will hold an investor briefing at 10:00am (AEDT) on the same day.

The briefing will be hosted by Rick Ratliff (CEO & Managing Director) and Ancila Desai (CFO), who will present an update on the Company's quarterly progress, followed by a Q&A session.

To participate, please register at:

[https://us02web.zoom.us/webinar/register/WN\\_a8ceN8ROS1qN5sVJKyMDzA](https://us02web.zoom.us/webinar/register/WN_a8ceN8ROS1qN5sVJKyMDzA)

– ENDS –

*This document has been authorised for release by Rick Ratliff, CEO & Managing Director.*

**For more information please contact:****Company**

Ancila Desai  
Chief Financial Officer  
[corporate@medadvisor.com.au](mailto:corporate@medadvisor.com.au)

**Investors**

Ronn Bechler  
[ronn.bechler@atomicgroup.com.au](mailto:ronn.bechler@atomicgroup.com.au)  
+61 400 009 774

**About MedAdvisor**

MedAdvisor is a world-class medication management platform that empowers patients to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 25,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 2.9 million patients through over 90% of Australian pharmacies. MedAdvisor is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: [mymedadvisor.com/investors](http://mymedadvisor.com/investors)